Theriva Biologics Reports Exit/Disposal Costs
Ticker: TOVX · Form: 8-K · Filed: Oct 2, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $520,000, $2.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, corporate-action
TL;DR
Theriva Biologics is cleaning house, reporting exit costs as they restructure.
AI Summary
Theriva Biologics, Inc. filed an 8-K on October 2, 2025, reporting costs associated with exit or disposal activities as of September 28, 2025. The filing details the company's transition and restructuring efforts, though specific financial figures for these costs are not detailed in this excerpt.
Why It Matters
This filing indicates Theriva Biologics is undergoing significant restructuring, which could impact its future operations and strategic direction.
Risk Assessment
Risk Level: medium — Reporting exit and disposal costs suggests a period of significant change and potential financial strain for the company.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- September 28, 2025 (date) — Date of earliest event reported
- October 2, 2025 (date) — Filing Date
- Nevada (jurisdiction) — State of incorporation
- Rockville, Maryland (location) — Business Address
FAQ
What specific activities are associated with the exit or disposal costs reported by Theriva Biologics?
The provided excerpt does not specify the exact nature of the exit or disposal activities, only that costs are associated with them as of September 28, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported was as of September 28, 2025.
What is Theriva Biologics, Inc.'s state of incorporation?
Theriva Biologics, Inc. is incorporated in Nevada.
What is the business address of Theriva Biologics, Inc.?
The business address is 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850.
What is the filing date of this 8-K report?
This 8-K report was filed on October 2, 2025.
Filing Stats: 889 words · 4 min read · ~3 pages · Grade level 13.6 · Accepted 2025-10-02 16:01:22
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
- $520,000 — it will incur a total of approximately $520,000 in charges in connection with the workf
- $2.0 million — Plan is expected to save approximately $2.0 million in compensation and benefits annually,
Filing Documents
- tm2527561d1_8k.htm (8-K) — 29KB
- 0001104659-25-096047.txt ( ) — 193KB
- syn-20250928.xsd (EX-101.SCH) — 3KB
- syn-20250928_lab.xml (EX-101.LAB) — 33KB
- syn-20250928_pre.xml (EX-101.PRE) — 22KB
- tm2527561d1_8k_htm.xml (XML) — 4KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. On September 28, 2025, the Board of Directors of Theriva Biologics, Inc. (the "Company") approved a plan to resize and restructure the Company (the "Plan") for purposes of focusing its attention on business development and licensing activities and the Company's upcoming meetings with the U.S. Food and Drug Administration and the European Medicines Agency for planned clinical trials in patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") and retinoblastoma. The Company's lead product candidate, VCN-01, a clinical stage oncolytic human adenovirus that is modified for tumor-selective replication and to express an enzyme, PH20 or hyaluronidase, has been evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer ("VIRAGE"), and has recently been used to treat patients in a Phase 1 clinical study for the treatment of retinoblastoma. Pursuant to the Plan, on September 30, 2025, the Company implemented a workforce reduction of approximately seven employees or 32% of the current global Company workforce. The goal of this reduction is to direct the Company's resources towards business development and licensing activities and clinical trial plans and preparation for VCN-01 in patients with PDAC and retinoblastoma, which it believes will represent its best opportunity for success. The Company expects to substantially complete the employee reduction immediately and estimates that it will incur a total of approximately $520,000 in charges in connection with the workforce reduction, all of which is expected to be incurred in the fourth quarter of 2025. These charges consist primarily of cash severance and benefits over a three-month period, in connection with the workforce reduction. The Plan is expected to save approximately $2.0 million in compensation and benefits annually, and together with additional anticipated operating cost reductions the Company expects that it will extend its
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 2, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer